Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT02624596
PHASE2
Understanding How Ketamine Brings About Rapid Improvement in OCD
Sponsor: Stanford University
View on ClinicalTrials.gov
Summary
The purpose of this study is to understand how ketamine brings about rapid improvement in Obsessive-Compulsive Disorder (OCD) symptoms.
Official title: NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2016-06
Completion Date
2026-06
Last Updated
2025-05-31
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Ketamine
OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
DRUG
Midazolam
OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
Locations (1)
Stanford University
Stanford, California, United States